October 30, 2018
Humacyte launches Phase II vascular trauma Humacyl vessel trial
Humacyte said yesterday it launched a U.S. Phase II trial of its Humacyl investigational human acellular vessel exploring the systems’ use for vascular replacement or reconstruction in patients with life or limb-threatening vascular trauma.
The company based out of RTP, N.C. hopes to enroll 40 adults at six U.S. sites for this trial, with monitoring of patients extended to 24 months.
“As a world leader in trauma research, we are constantly exploring new and innovative approaches to treating life threatening injuries. We look forward to evaluating this bioengineered blood vessel in the treatment of appropriate patients requiring vascular surgical repair,” Dr. Thomas Scalea of the University of Maryland’s R Adams Cowley Shock Trauma Center said in a prepared release.